# LITESPARK-024 (NCT05468697)

> A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

No report yet. It can be ordered.

- Drugs tested: belzutifan plus palbociclib
- Indication: advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05468697
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Belzutifan; Palbociclib
- Enrollment: 60
- Primary outcome: Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)
- Primary outcome: Number of Participants Who Experience at Least One Adverse Event (AE)
- Primary outcome: Number of Participants Who Discontinue Study Treatment Due to an AE

## Indexed commentary on LITESPARK-024 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=litespark-024-nct05468697

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05468697", "email": "<work email>"}; the inbox owner confirms by the emailed link.